Demographic and clinical characteristics of the study population in total, and assigned according to degree of CR (sCR or non-sCR)
| Characteristic . | All (N = 769) . | sCR (n = 360) . | Non-sCR (n = 409) . | |||
|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | |
| Age, y | ||||||
| Median (IQR) | 56.6 (45.4-65.3) | 39.3 | 54.5 (43.4-64.0) | 35.3 | 58.6 (47.2-65.7) | 42.8 |
| ≥60 | 302 | 127 | 175 | |||
| Sex | ||||||
| Male | 406 | 52.8 | 180 | 50.0 | 226 | 55.3 |
| Female | 363 | 47.2 | 180 | 50.0 | 183 | 44.7 |
| Year of diagnosis | ||||||
| 2000-2002 | 199 | 25.9 | 66 | 18.3 | 133 | 32.5 |
| 2003-2010 | 570 | 74.1 | 294 | 81.7 | 276 | 67.5 |
| WHO performance score at diagnosis | ||||||
| <2 | 647 | 84.1 | 306 | 85.0 | 341 | 83.4 |
| ≥2 | 122 | 15.9 | 54 | 15.0 | 68 | 16.6 |
| AML classification | ||||||
| De novo | 638 | 83.0 | 311 | 86.4 | 327 | 80.0 |
| Secondary* | 105 | 13.7 | 38 | 10.6 | 67 | 16.4 |
| Therapy related | 26 | 3.4 | 11 | 3.1 | 15 | 3.7 |
| Cytogenetic risk group | ||||||
| Favorable | 49 | 5.2 | 20 | 5.6 | 20 | 4.9 |
| Intermediate | 554 | 72.0 | 258 | 71.7 | 296 | 72.4 |
| Unfavorable | 104 | 13.5 | 58 | 16.1 | 46 | 11.2 |
| Missing | 71 | 9.2 | 24 | 6.7 | 47 | 11.5 |
| Characteristics at time of diagnosis, median (IQR) | ||||||
| Bone marrow blast count, % | 55 (33-80) | 60 (35-80) | 51 (32-80) | |||
| Blast count blood, % | 29 (9-65) | 28 (8-70) | 30 (4-59) | |||
| Leukocytes, × 109/L | 10.8 (2.4-44.7) | 11.1 (2.8-42.8) | 9.7 (2.2-46) | |||
| Platelets, × 109/L | 54 (30-103) | 63 (33-122.5) | 49 (25-86) | |||
| Days between the first day of treatment and CR evaluation (IQR) | 31 (27-35) | 30 (27-35) | 31 (27-37) | |||
| Days at risk for RBC transfusion (IQR)† | 8 (6-13) | 7 (6-13) | 8 (6-12) | |||
| Characteristic . | All (N = 769) . | sCR (n = 360) . | Non-sCR (n = 409) . | |||
|---|---|---|---|---|---|---|
| N . | % . | N . | % . | N . | % . | |
| Age, y | ||||||
| Median (IQR) | 56.6 (45.4-65.3) | 39.3 | 54.5 (43.4-64.0) | 35.3 | 58.6 (47.2-65.7) | 42.8 |
| ≥60 | 302 | 127 | 175 | |||
| Sex | ||||||
| Male | 406 | 52.8 | 180 | 50.0 | 226 | 55.3 |
| Female | 363 | 47.2 | 180 | 50.0 | 183 | 44.7 |
| Year of diagnosis | ||||||
| 2000-2002 | 199 | 25.9 | 66 | 18.3 | 133 | 32.5 |
| 2003-2010 | 570 | 74.1 | 294 | 81.7 | 276 | 67.5 |
| WHO performance score at diagnosis | ||||||
| <2 | 647 | 84.1 | 306 | 85.0 | 341 | 83.4 |
| ≥2 | 122 | 15.9 | 54 | 15.0 | 68 | 16.6 |
| AML classification | ||||||
| De novo | 638 | 83.0 | 311 | 86.4 | 327 | 80.0 |
| Secondary* | 105 | 13.7 | 38 | 10.6 | 67 | 16.4 |
| Therapy related | 26 | 3.4 | 11 | 3.1 | 15 | 3.7 |
| Cytogenetic risk group | ||||||
| Favorable | 49 | 5.2 | 20 | 5.6 | 20 | 4.9 |
| Intermediate | 554 | 72.0 | 258 | 71.7 | 296 | 72.4 |
| Unfavorable | 104 | 13.5 | 58 | 16.1 | 46 | 11.2 |
| Missing | 71 | 9.2 | 24 | 6.7 | 47 | 11.5 |
| Characteristics at time of diagnosis, median (IQR) | ||||||
| Bone marrow blast count, % | 55 (33-80) | 60 (35-80) | 51 (32-80) | |||
| Blast count blood, % | 29 (9-65) | 28 (8-70) | 30 (4-59) | |||
| Leukocytes, × 109/L | 10.8 (2.4-44.7) | 11.1 (2.8-42.8) | 9.7 (2.2-46) | |||
| Platelets, × 109/L | 54 (30-103) | 63 (33-122.5) | 49 (25-86) | |||
| Days between the first day of treatment and CR evaluation (IQR) | 31 (27-35) | 30 (27-35) | 31 (27-37) | |||
| Days at risk for RBC transfusion (IQR)† | 8 (6-13) | 7 (6-13) | 8 (6-12) | |||